| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 310 | 310 | 230 | 20,380 | 0 |
| Sales Growth | unch | +34.78% | -98.87% | unch | unch |
| Net Income | -149,270 | -40,220 | -152,390 | -167,810 | -169,840 |
| Net Income Growth | -271.13% | +73.61% | +9.19% | +1.20% | -1,101.13% |
Atai Beckley N.V. (ATAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AtaiBeckley N.V. is a clinical-stage biopharmaceutical company which focused on mental health treatments. AtaiBeckley N.V., formerly known as atai Life Sciences, is based in NEW YORK.
Fiscal Year End Date: 12/31